1. Home
  2. HRMY vs SEMR Comparison

HRMY vs SEMR Comparison

Compare HRMY & SEMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$27.07

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo SEMrush Holdings Inc.

SEMR

SEMrush Holdings Inc.

HOLD

Current Price

$11.95

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
SEMR
Founded
2017
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
HRMY
SEMR
Price
$27.07
$11.95
Analyst Decision
Buy
Hold
Analyst Count
10
5
Target Price
$46.70
$10.00
AVG Volume (30 Days)
630.7K
1.1M
Earning Date
05-05-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
7.97
N/A
EPS
2.71
N/A
Revenue
$868,453,000.00
$443,644,000.00
Revenue This Year
$19.75
$16.85
Revenue Next Year
$12.88
$14.35
P/E Ratio
$9.79
N/A
Revenue Growth
21.51
17.74
52 Week Low
$25.52
$6.56
52 Week High
$40.87
$11.95

Technical Indicators

Market Signals
Indicator
HRMY
SEMR
Relative Strength Index (RSI) 35.59 67.70
Support Level $25.71 $11.90
Resistance Level $28.99 N/A
Average True Range (ATR) 0.72 0.02
MACD 0.18 -0.00
Stochastic Oscillator 28.44 73.21

Price Performance

Historical Comparison
HRMY
SEMR

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About SEMR SEMrush Holdings Inc.

SEMrush Holdings Inc offers an online visibility management software-as-a-service (SaaS) platform enabling its clients globally to identify and reach the right audience for their content. The platform utilizes data and intelligence at the core, surrounded by AI-powered interconnected hubs to provide customers with key data, helping them understand trends and derive actionable insights to improve their websites and social media pages, and distribute relevant content to their targeted customers across a variety of digital channels. The company generates nearly all of its revenue from subscriptions to its online visibility management SaaS platform under a SaaS model. Geographically, it generates maximum revenue from the United States, followed by the United Kingdom and other regions.

Share on Social Networks: